CJC-1295 With and Without DAC: Understanding the Difference

Few peptides have shaped modern growth hormone research like CJC-1295. Originally developed in the mid-2000s as a long-acting analog of growth hormone-releasing hormone (GHRH), this compound has since become a reference tool for studying the GH/IGF-1 axis. In this article, the Peptidos Research Team breaks down what CJC-1295 is, how its two variants differ, what the published data shows, and what still needs answering.

What Is CJC-1295?

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), the hypothalamic hormone that signals the pituitary gland to release growth hormone. The molecule is built from the active 1-29 fragment of native GHRH and incorporates four targeted amino acid substitutions — D-Ala at position 2, Gln at 8, Ala at 15, and Leu at 27 — designed to make the peptide resistant to enzymatic breakdown by dipeptidyl peptidase-4 (DPP-4).

In its native form, GHRH has a half-life of only a few minutes because DPP-4 rapidly cleaves it in plasma. The substitutions in CJC-1295 dramatically extend that window, turning a fragile signaling peptide into a stable research tool. The compound was originally developed by ConjuChem, a Canadian biotechnology company, and entered clinical investigation in the mid-2000s.

What makes CJC-1295 especially interesting is that it exists in two distinct forms with very different pharmacokinetic profiles — and this is where most of the confusion in the peptide research space comes from.

CJC-1295 With DAC vs Without DAC

The two variants share the same core 1-29 sequence, but only one of them carries a Drug Affinity Complex (DAC). That single structural difference fundamentally changes how the peptide behaves in the body.

• CJC-1295 with DAC has a lysine-linked maleimidopropionyl group attached at position 30. This chemical "anchor" allows the peptide to covalently bind to circulating serum albumin, the most abundant protein in plasma. Once bound, albumin acts as a slow-release depot, protecting the peptide from clearance and dragging the active compound along for the ride. Published data in healthy adults showed an estimated half-life of 5.8 to 8.1 days, with mean IGF-1 levels remaining above baseline for up to 28 days after multiple doses. In other words, one injection produces a sustained elevation in basal GH and IGF-1 levels that lasts roughly a week.

• CJC-1295 without DAC, often referred to as Modified GRF 1-29 (or Mod GRF 1-29), lacks the albumin-binding group. Its half-life drops back down to roughly 30 minutes. This shorter window means it produces a sharp, transient pulse of GH release rather than a sustained elevation, which more closely resembles the body's natural pulsatile pattern of GH secretion.

The practical and biological implications of this difference are significant:

• Pulsatility: GH is normally released in pulses, with peaks during deep sleep and troughs throughout the day. The non-DAC version preserves this rhythm. The DAC version raises the baseline of GH secretion without altering the frequency or amplitude of natural pulses, effectively shifting the entire curve upward.
• Dosing frequency in research models: DAC-modified CJC-1295 has been studied with weekly or biweekly administration. The non-DAC version requires more frequent administration to sustain effects.
• IGF-1 dynamics: Sustained DAC exposure produces a steady IGF-1 elevation, while the non-DAC variant generates more transient changes.

Neither version is universally "better" — they're tools for different research questions. Investigators studying chronic GH/IGF-1 axis modulation tend to use the DAC form. Those studying acute pulse dynamics or trying to mimic physiological release patterns tend to use no DAC version.

How CJC-1295 Works

CJC-1295 binds to GHRH receptors on somatotroph cells in the anterior pituitary gland. This activates adenylate cyclase, raises intracellular cyclic AMP (cAMP), and triggers the synthesis and release of growth hormone. The released GH then travels to the liver and other peripheral tissues, where it stimulates the production of insulin-like growth factor-1 (IGF-1) — the downstream mediator responsible for many of GH's anabolic and metabolic effects.

Importantly, CJC-1295 works upstream of the pituitary rather than replacing GH directly. This means the body's normal feedback loops — including somatostatin-mediated inhibition — remain intact, which is one reason researchers consider it a more physiological tool than exogenous recombinant GH.

What the Research Has Found

Effects on GH and IGF-1 Secretion

The clearest and most consistent finding across decades of research is that CJC-1295 reliably increases both GH and IGF-1. In a foundational 2006 study published in The Journal of Clinical Endocrinology & Metabolism, single subcutaneous doses produced 2- to 10-fold increases in mean plasma GH for six days or more and 1.5- to 3-fold increases in plasma IGF-1 for 9 to 11 days. After repeat dosing, IGF-1 levels stayed elevated for nearly a month.

Crucially, these elevations occurred without disrupting the natural pulsatility of GH secretion — the peptide raised the trough levels rather than flattening the curve.

Body Composition and Metabolism

Because GH and IGF-1 are central regulators of lean mass, fat mobilization, and protein metabolism, much of the research interest in CJC-1295 has focused on body composition. Animal studies show effects consistent with sustained GH/IGF-1 elevation: increased lean tissue, enhanced lipolysis through hormone-sensitive lipase activation, and improved protein synthesis via mTOR and PI3K/Akt pathways. A landmark study in GHRH-knockout mice demonstrated that once-daily CJC-1295 administration normalized growth, somatotroph cell proliferation, and IGF-1 secretion — essentially restoring a functional GH axis in animals genetically incapable of producing GHRH.

Tissue Repair and Recovery

GH and IGF-1 play well-established roles in collagen synthesis, satellite cell activation, and connective tissue remodeling. Preclinical work suggests CJC-1295 can enhance these processes indirectly by elevating the relevant hormonal signals, though dedicated tissue-repair studies on CJC-1295 itself are far more limited than for peptides like BPC-157.

Sleep and Recovery Markers

Because the largest natural GH pulse occurs during slow-wave sleep, several research groups have investigated whether CJC-1295 influences sleep architecture. Early data suggest it may enhance slow-wave sleep duration, though human evidence here remains preliminary.

The Human Evidence: What We Actually Know

Despite a robust pharmacokinetic profile, the human clinical literature on CJC-1295 is surprisingly thin. The most substantial human data come from early phase studies conducted by ConjuChem:

• Phase I/II safety and pharmacokinetic studies (2005–2006): Healthy adult volunteers tolerated single subcutaneous doses up to 60 μg/kg without serious adverse events. GH and IGF-1 increases were dose-dependent and prolonged.
• Phase II trial in HIV-associated lipodystrophy: This trial was discontinued after the death of one participant. The cause of death was not formally attributed to CJC-1295, but the event ended further clinical development of the compound by ConjuChem.

Beyond these trials, large-scale human safety data simply doesn't exist. Most of what is reported anecdotally about CJC-1295 in humans comes from off-label compounding pharmacy use rather than controlled studies.

Safety Considerations

Reported and theoretical concerns include:

• Glucose metabolism: GH excess can reduce insulin sensitivity, and sustained IGF-1 elevation may shift glucose handling.
• Cardiovascular signals: The FDA has cited heart-related adverse events in its review of compounded CJC-1295.
• Long-term IGF-1 elevation: Chronic elevation of IGF-1 is biologically active in tissues beyond the intended target, and the long-term consequences in humans haven't been studied.
• Immunogenicity and impurity risks: As with many compounded peptides, the FDA has flagged concerns about peptide-related impurities and potential immune reactions.

Most of these concerns reflect the absence of large, long-term human data rather than confirmed harm. But the absence of evidence is not evidence of safety.

Regulatory Status

CJC-1295 is not approved as a medicine by the FDA, EMA, or any major regulator. It reached Phase II development in the mid-2000s but never advanced further.

In the United States, the FDA originally placed CJC-1295 on its Category 2 list of "bulk drug substances with safety concerns," which restricted compounding pharmacies from producing it. In September 2024, the FDA removed CJC-1295 from Category 2, sending it back to the Pharmacy Compounding Advisory Committee (PCAC) for further review. As of early 2026, this regulatory limbo continues — the compound is no longer formally classified as having safety concerns, but it is also not approved or cleared for routine compounding.

In Europe, CJC-1295 is not licensed as a medicine and cannot be sold as a supplement, but it is not a controlled substance in most EU countries and can be possessed for legitimate research purposes.

The World Anti-Doping Agency (WADA) classifies CJC-1295 under Section S2 of the Prohibited List as a peptide hormone and growth factor releasing agent. Athletes subject to WADA testing cannot use it at any time, in or out of competition.

Key Takeaway on CJC-1295

CJC-1295 is one of the most pharmacologically well-characterized GHRH analogs ever developed. The mechanism is clear, the GH/IGF-1 effects are reproducible, and the difference between the DAC and non-DAC versions gives researchers two genuinely distinct tools for studying growth hormone biology. At the same time, the human safety database is small, large-scale clinical trials were never completed, and regulatory status remains unsettled. For now, CJC-1295 sits in a familiar position for high-potential peptides: scientifically compelling, clinically underdeveloped, and likely to remain a research-only compound until proper trials catch up with the preclinical promise.